Korea Arlico Pharm Co.,Ltd. (KOSDAQ:A260660) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its shares, pursuant to a contract with Samsung Securities Co., Ltd. The purpose of the program is stabilizing share prices, raising shareholder value and compensating employee performance. The program will expire on February 19, 2019. As of August 19, 2018, the company had no shares in treasury within scope available for dividend and no shares in treasury under other capacities.